Half-year report · HY
4576.TEDINET S100YVEU
Period2026-01-01 → 2026-06-30
Filed2026-08-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥33m | 2026-01-01 → 2026-06-30 | Cons. | Net sales |
| Revenue | ¥388m | 2025-01-01 → 2025-12-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥173m | 2025-01-01 → 2025-06-30 | Cons. | Net sales |
| Operating income | −¥313m | 2026-01-01 → 2026-06-30 | Cons. | Operating income |
| Operating income | −¥309m | 2025-01-01 → 2025-06-30 | Cons. | Operating income |
| Ordinary income | −¥322m | 2026-01-01 → 2026-06-30 | Cons. | Ordinary income |
| Ordinary income | −¥630m | 2025-01-01 → 2025-12-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | −¥316m | 2025-01-01 → 2025-06-30 | Cons. | Ordinary income |
| Profit before tax | −¥322m | 2026-01-01 → 2026-06-30 | Cons. | Income before income taxes |
| Profit before tax | −¥316m | 2025-01-01 → 2025-06-30 | Cons. | Income before income taxes |
| Net income (owners) | −¥323m | 2026-01-01 → 2026-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥632m | 2025-01-01 → 2025-12-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥317m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | −¥323m | 2026-01-01 → 2026-06-30 | Cons. | Profit loss |
| Net income | −¥317m | 2025-01-01 → 2025-06-30 | Cons. | Profit loss |
| Total assets | ¥2.0bn | at 2026-06-30 | Cons. | Assets |
| Total assets | ¥2.2bn | at 2025-12-31 | Cons. | Assets |
| Total assets | ¥1.5bn | at 2025-06-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥641m | at 2026-06-30 | Cons. | Liabilities |
| Total liabilities | ¥734m | at 2025-12-31 | Cons. | Liabilities |
| Net assets / equity | ¥1.4bn | at 2026-06-30 | Cons. | Net assets |
| Net assets / equity | ¥1.4bn | at 2025-12-31 | Cons. | Net assets |
| Net assets / equity | ¥885m | at 2025-06-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥1.6bn | at 2026-06-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.7bn | at 2025-12-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥987m | at 2026-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.7bn | at 2025-12-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.0bn | at 2025-06-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.1bn | at 2024-12-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥344m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | −¥494m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥211m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥602m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥2m | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥222m | 2026-01-01 → 2026-06-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥1.1bn | 2025-01-01 → 2025-12-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥136m | 2025-01-01 → 2025-06-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥-5.8 | 2026-01-01 → 2026-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-13.19 | 2025-01-01 → 2025-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-7.08 | 2025-01-01 → 2025-06-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 68.7% | at 2026-06-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.1% | at 2025-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.4% | at 2025-06-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
All source rows · 387
| Item | Context | Value | Unit |
|---|---|---|---|
| Proceeds from long term loans payable fin cf | Prior1InterimDuration | 32000000 | JPY |
| Proceeds from long term loans payable fin cf | InterimDuration | － | JPY |
| Repayment of long term loans payable fin cf | Prior1InterimDuration | -9524000 | JPY |
| Repayment of long term loans payable fin cf | InterimDuration | -22024000 | JPY |
| Redemption of bonds fin cf | Prior1InterimDuration | -302500000 | JPY |
| Redemption of bonds fin cf | InterimDuration | － | JPY |
| Proceeds from issuance of common stock fin cf | Prior1InterimDuration | － | JPY |
| Proceeds from issuance of common stock fin cf | InterimDuration | 194829000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | Prior1InterimDuration | 415921000 | JPY |
| Proceeds from issuance of stock resulting from exercise of subscription rights to shares fin cf | InterimDuration | 49445000 | JPY |
| Purchase of treasury stock fin cf | Prior1InterimDuration | － | JPY |
| Purchase of treasury stock fin cf | InterimDuration | -0 | JPY |
| Commission expenses paid fin cf | Prior1InterimDuration | -32000 | JPY |
| Commission expenses paid fin cf | InterimDuration | -0 | JPY |
| Net cash provided by used in financing activities | Prior1InterimDuration | 135864000 | JPY |
| Net cash provided by used in financing activities | InterimDuration | 222250000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1InterimDuration | -218000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | InterimDuration | 107000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1InterimDuration | -78173000 | JPY |
| Net increase decrease in cash and cash equivalents | InterimDuration | -723252000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 1126035000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 1709790000 | JPY |
| Cash and cash equivalents | Prior1InterimInstant | 1047861000 | JPY |
| Cash and cash equivalents | InterimInstant | 986537000 | JPY |
| Directors compensations sga | Prior1InterimDuration | 69512000 | JPY |
| Directors compensations sga | InterimDuration | 49660000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)半期報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条の５第１項の表の第１号 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)東海財務局長 | |
| Filing date cover page | FilingDateInstant | 2026-08-13 | |
| Semi annual accounting period cover page | FilingDateInstant | Original text (Japanese)第29期中（自 2026年１月１日 至 2026年６月30日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)株式会社デ・ウエスタン・セラピテクス研究所 | |
| Company name in english cover page | FilingDateInstant | D.Western Therapeutics Institute, Inc. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 日 高 有 一 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)名古屋市中区錦一丁目18番11号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 052－218－8785 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役 松 原 さ や 子 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)名古屋市中区錦一丁目18番11号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 052－218－8785 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役 松 原 さ や 子 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E22024 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 45760 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)株式会社デ・ウエスタン・セラピテクス研究所 | |
| Filer name in english | FilingDateInstant | D.Western Therapeutics Institute, Inc. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第四号の三様式 |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |